Press "Enter" to skip to content

New patent for Astrazeneca Ab drug BYDUREON PEN

0
Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug BYDUREON PEN

Annual Drug Patent Expirations for BYDUREON+PEN
Annual Drug Patent Expirations for BYDUREON+PEN

Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-nine patents protecting this drug.

This drug has four hundred and sixty-eight patent family members in forty-eight countries.

The generic ingredient in BYDUREON PEN is exenatide synthetic. One supplier is listed for this compound. Additional details are available on the exenatide synthetic profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca Ab drug BYDUREON PEN
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    DrugPatentWatch - Make Better Decisions